Surims Ltd Logo
 
 
 
 
 
 
BD Banner Ad
 

Search the News on Pharmaceutical Services

A comprehensive source of news from the pharmaceutical industry. With the latest from pharmaceutical organisations around the globe, we deliver an extensive summary of news, press releases and information from businesses and authoritative news sources. Search and filter the results by company or location to find the news that matters to you.

 
Search Term
 
 
Sector
 
 
Country
 
 

Save This Search | View as Grid | Order by Recently Added | Order by Company Name

  • Total Results: 615
  • Total Pages: 31
 
 
 
West Pharmaceutical Products Ireland Ltd Logo
 
 
Covid vaccine packaging group doubles Waterford staff
 
US pharma group makes stoppers for vials of Covid-19 vaccine. West Pharmaceuticals has doubled its Waterford workforce to meet demand for Covid-19 medical supplies. West specialises in packaging for injectible drugs. That includes stoppers for vials of Covid-19 vaccines. The company says it is involved with more than 90 per cent of the companies that have Covid-19 vaccines or vaccine candidates in phase-three trials. That has seen the US group scale up operations and working schedules at the Waterford plant that it opened in 2018 in response to a surge in customer demand…
 

Read more on this story »

Basic Profile
 
Eli Lilly Logo
 
Eli Lilly - 17 May 2021
 
Eli Lilly appoints 3 Indian Pharma Companies —Cipla, Lupin and Sun Pharma to bolster supply of COVID-19 drug baricitinib
 
INDIANAPOLIS, May 4, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announces new initiatives to help COVID-19 patients in India as part of its commitment to bring the full force of its scientific and medical expertise to attack the coronavirus pandemic around the world. Lilly is offering donations of baricitinib to the Indian government through Direct Relief while simultaneously working with local Indian pharmaceutical companies to execute royalty-free voluntary licensing agreements to accelerate the manufacturing and distribution…
 

Read more on this story »

Basic Profile
 
Catalent Pharma Solutions Logo
 
 
HBC Announces Global Innovation Partnership
 
Hofseth BioCare ASA (HBC), a Norwegian biotech company that develops high-value ingredients and finished products, today announced that it has begun a global innovation partnership with Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, to develop a delayed-release formulation of HBC’s OmeGo® fish oil.
 

View original story »

Basic Profile
 
Aenova Holding GmbH Logo
 
Aenova Holding GmbH - 11 May 2021
 
Aenova significantly expands capacity for Fill&Finish of Vaccines and Biologics
 
Latina, 07/05/2021 In order to expand its fill and finish capacity for the production of Biologics and especially BSL1 and BSL2 vaccines against the SARS-CoV-2 virus, the Aenova Group is currently building a new sterile production area at its site in Latina, Italy. With an investment volume of more than 16 million euros, the focus is on a new "Fill and Finish" area for vials and prefilled syringes (PFS) with high-speed filling lines including compounding. The first line to be installed has a capacity of more than 80 million vials (glass…
 

Read more on this story »

Basic Profile
 
NJ Biopharmaceuticals Logo
 
NJ Biopharmaceuticals - 11 May 2021
 
NJ Bio Moves Headquarters to Princeton, New Jersey
 
PRINCETON, N.J.--(BUSINESS WIRE)--NJ Biopharmaceuticals LLC (d/b/a NJ Bio), an expert provider of chemistry and biopharmaceutical services specializing in bioconjugation, custom synthesis, flow chemistry, and process development, announced the move of its headquarters from North Brunswick to Princeton, New Jersey. The 35,000-square-foot, state-of-the-art laboratory space will be located at 350 Carter Road, at a site formerly occupied by 
 

Read more on this story »

Basic Profile
 
Moderna Logo
 
Moderna - 08 May 2021
 
Moderna Announces New Supply Agreement with Switzerland for 7 Million Booster Vaccine Doses in 2022
 
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 6, 2021-- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a new supply agreement with the Swiss Federal Government for 7 million doses of booster vaccine in 2022, with an additional option for another 7 million doses for delivery during the second half of 2022 or first quarter of 2023. Purchase under this agreement is subject to regulatory approval of the booster vaccine candidate. Today’s announcement follows two earlier agreements between Switzerland and Moderna to…
 

Read more on this story »

Basic Profile
 
3P Biopharmaceuticals Logo
 
3P Biopharmaceuticals - 08 May 2021
 
3P Biopharmaceuticals and Buzzard Pharmaceuticals start a collaboration
 
3P Biopharmaceuticals and Buzzard Pharmaceuticals have entered into a partnership agreement for manufacturing of the potent IL-1 inhibitor Isunakinra, a recombinant protein for cancer indications. 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organisation CDMO specialized in the process development and GMP manufacturing of biologics and Buzzard…
 

Read more on this story »

Basic Profile
 
GSK Logo
 
GSK - 08 May 2021
 
GSK Supports Manufacture of Novavax’ COVID-19 Vaccine
 
Novavax, GSK and the UK Government Vaccines Taskforce have reached an agreement in principle to support manufacturing of up to 60 million doses of Novavax’ COVID-19 vaccine candidate (NVX-CoV2373) for use in the UK. GSK will provide fill and finish manufacturing capacity at its Barnard Castle facility in the North East of England beginning as early as May 2021, with a rapid technology transfer between the two companies beginning immediately. GSK and Novavax will negotiate a final agreement to include additional terms and conditions.
 

View original story »

Basic Profile
 
Lonza Group Logo
 
Lonza Group - 03 May 2021
 
Lonza and Moderna Enter to Double Drug Substance Production for COVID-19 Vaccine in Visp
 
New agreement for three further production lines at Lonza’s site in Visp, Switzerland Additional production lines will come online sequentially All three are expected to be operational in the earlier part of 2022 Basel, Switzerland, 29 April 2021 – Lonza today announced the expansion of its collaboration with Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, to manufacture the drug substance for the COVID-19 Vaccine Moderna. The expanded collaboration provides for the…
 

Read more on this story »

Premium+ Profile
 
Forge Biologics Logo
 
Forge Biologics - 02 May 2021
 
Gene therapy 'development engine' scores $120M to beef up contract manufacturing
 
COLUMBUS, OH, April 29, 2021 – Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced the closing of a $120 million Series B financing. The financing was led by RA Capital Management with participation from Perceptive Advisors and related affiliates, Surveyor Capital (a Citadel company), Octagon Capital, and Marshall Wace.  Existing investors Perceptive Xontogeny Venture Fund and Drive Capital also participated. In connection with the financing, Matthew Hammond, Ph.D., of RA Capital, and Fred Callori of the Perceptive Xontogeny Venture Fund…
 

Read more on this story »

Basic Profile
 
PPD Logo
 
PPD - 01 May 2021
 
PPD TO EXPAND GMP LAB IN IRELAND TO ENHANCE BIOPHARMACEUTICAL TESTING CAPABILITIES
 
WILMINGTON, N.C. (April 28, 2021) –  PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, is expanding its Athlone, Ireland, GMP (good manufacturing practices) laboratory, significantly increasing the size of its current facility and adding cell and gene therapy testing to…
 

Read more on this story »

Basic Profile
 
Formulationbio Logo
 
Formulationbio - 27 Apr 2021
 
News Update: Custom Pharmaceutical Excipients Development Service Available at Formulationbio
 
Known as not only a provider of various excipients but also a CRO for pharmaceutical formulation, Formulationbio announces to provide tailor-made pharmaceutical excipients development service for customers across the globe on April 20, 2021. Excipients…
 

Read more on this story »

Basic Profile
 
Minapharm Logo
 
Minapharm - 27 Apr 2021
 
RDIF and Minapharm Agree to Produce over 40 Million Doses of the Sputnik V Vaccine in Egypt
 
Moscow/Cairo/Berlin, April 22, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), Egypt’s Minapharm, the regional leader in recombinant DNA technology, and its Berlin-based subsidiary ProBioGen AG announce the agreement to produce over 40 million doses per year of the world’s first registered vaccine against COVID-19, Sputnik V. The parties intend to commence technology transfer immediately. The rollout of the vaccine is expected in 3Q 2021. RDIF and Minapharm will initially…
 

Read more on this story »

Basic Profile
 
Hualan Biological Engineering Inc Logo
 
 
RDIF, Hualan Ink COVID-19 Vaccine Deal
 
Deal calls for production of over 100 million doses of Sputnik V vaccine in China.
The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and Hualan Biological Bacterin Inc., a subsidiary company of one of China’s leading biopharmaceutical producers and the largest influenza vaccine manufacturer, Hualan Biological Engineering Inc., have entered an agreement to produce over 100 million doses per year of the Sputnik V vaccine in China.
 

View original story »

Basic Profile
 
Sharp Logo
 
Sharp - 27 Apr 2021
 
Sharp Expanding with Third Pennsylvania Location
 
Harrisburg, PA – Today, Governor Tom Wolf announced that Sharp, a global leader in advanced clinical supply chain services and contract pharmaceutical packaging with a strong presence in Pennsylvania, will expand operations at existing facilities in Allentown and Conshohocken and into a third facility in Macungie Borough, Lehigh County, retaining 1,092 current positions and creating 335 new, full-time jobs over the next three years. “My administration is thrilled to support Sharp—whose…
 

Read more on this story »

Basic Profile
 
Evotec AG Logo
 
Evotec AG - 23 Apr 2021
 
Evotec starts work on $180M French companion to its biologics 'facility of the future' in Washington
 
Hamburg, Germany, 20 April 2021:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the Company has initiated the construction of its J.POD® 2 EU biologics manufacturing facility at Evotec’s Campus Curie in Toulouse, France. J.POD® 2 EU, Evotec’s second innovative cGMP biomanufacturing facility, will employ Just – Evotec Biologics’ cutting-edge technology that utilizes small, automated, highly intensified and continuous bioprocessing operations…
 

Read more on this story »

Basic Profile
 
Bristol-Myers Squibb Logo
 
Bristol-Myers Squibb - 22 Apr 2021
 
Bristol Myers Squibb Invests in Europe with New Cell Therapy Manufacturing Site Planned in the Netherlands
 
Bristol Myers Squibb announced the company has selected Leiden, Netherlands to house a new cell therapy manufacturing site in Europe, leveraging the growing life sciences region near Amsterdam and convenient access to transportation for shipping patient cells. As part of Bristol Myers Squibb’s continuing commitment to patients with aggressive hematological cancers and its growing cell therapy franchise, the company is making this significant new investment to expand global manufacturing capacity and bring treatments to patients faster. Leiden…
 

Read more on this story »

Basic Profile
 
The Pharmaceutical Services Directory Logo
 
 
FDA orders shutdown at Emergent's troubled plant 2 weeks after handing J&J the keys
 
Johnson & Johnson’s takeover of COVID-19 vaccine manufacturing at an error-prone Emergent BioSolutions plant in Baltimore didn’t last long.   Two weeks after the U.S. stepped in and handed control of vaccine manufacturing at the plant to J&J, Emergent agreed to temporarily halt producing new drug substance there.  In March, the factory had to discard up to 15 million vaccine doses when it mixed up materials for the J&J and AstraZeneca vaccines. The New York Times 
 

Read more on this story »

Basic Profile
 
Abzena Plc Logo
 
Abzena Plc - 20 Apr 2021
 
Abzena blueprints $200M biologics plant in North Carolina, where it plans to hire 325
 
Abzena is a Global Partner Research Organization (PRO) specializing in the integrated development and manufacture of complex biologics and bioconjugates has announced that the location of its new GMP manufacturing facility will be Sanford, North Carolina.   The significant expansion of Abzena’s capacity is driven by an increase in customer demand for commercial scale 2000L single use bioreactors across a wide range of therapeutic areas.  Sanford will be Abzena’s 6th site in a global network providing integrated solutions…
 

Read more on this story »

Basic Profile
 
Nexus Pharmaceuticals Logo
 
Nexus Pharmaceuticals - 16 Apr 2021
 
Nexus Pharmaceuticals sets month for $100M plant opening, preps drug for treating Covid patients
 
PLEASANT PRAIRIE, WI.–Nexus Pharmaceuticals Inc. plans to complete its nearly $100 million Pleasant Prairie sterile injectables plant in April 2021 and a company executive said it will help address the United States’ reliance on foreign pharmaceutical suppliers magnified by the Covid-19 pandemic.
 

Read more on this story »

Basic Profile
 
 
  • Total Results: 615
  • Total Pages: 31
 
 
TPSD Horizontal Banner
 
 

Pharmaceutical News

Keeping the latest and up-to-date news on our directory companies is a key activity of the editorial team.

We support companies directly through the profiles to allow them update their profile with the latest news and company announcements. Search fields are provided so that you can access news by company name, sector e.g research, manufacturing, equipment, packaging or geography. 

The global news is updated daily and its aim is to provide you as a directory user with the information needed to make good buying or supply choices. News covers companies operating within the pharmaceutical, biotechnology, medical device and nutraceutical sectors. 

Also through our software applications you can evaluate, rate and score news and company announcements to support corporate risk management activities. Through the software applications it is possible to supplement and add your own news items, keeping a library of news activities on any company identified through the directory. 

Take the Next Step

Should you have any questions or require further information please contact us ...
Contact the support team »

Check if your company is listed and claim your online profile ...
Search for your company listing »

If you're not listed in the directory and you want to build a public profile, register for an account ...
Register for an account to build a profile »

Apply for a free trial of our Supplier Management Software ...
Register for an account to trial the software »

 
PCI
 
Marouho vertical
 
Register small banner
 
small vertical ad
 
banner vertical
 
 
 
 
 
 
 

About Us

Surims Ltd is a consultancy established in 2003 supporting companies in the identification, qualification and management of quality vendors and suppliers in ingredients and formulations.

The Pharmaceutical Services Directory supports the identification and on-boarding of quality suppliers and also incorporates software features that manage relationships between suppliers and their customers. These include the building and deployment of questionnaires and assessments, electronic signatures and sign-offs and project management between vendor/partner and customer.

Access to the features and software is available on a 'pay as you go' basis, or a customised version can be licensed for your company for its own on-boarding and supplier management activities. Further information on our software services can be found at https://www.surims.com.

 
 
 

Get in Touch

The Pharmaceutical Services Directory
info@pharmaservicesdirectory.com

 
 

© 2021 Surims Ltd | All Rights Reserved.